DF-6002

N/A

Report date: 2025/02/02 20:00:08

Base Information

Drug NameDF-6002
Drug Alias NameDF-6002
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionImmunostimulantsInterleukin-12 replacementsNatural killer cells stimulants
TargetsInterleukin-12
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaFrance +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDragonfly Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesDragonfly Therapeutics LlcBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A